Clinical Trials
41
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
- Conditions
- Coronary Artery Disease (CAD)Peripheral Artery Disease (PAD)
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 277
- Registration Number
- NCT06052319
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸HCA Florida Memorial Hospital, Jacksonville, Florida, United States
🇺🇸University of Florida Health Jacksonville, Jacksonville, Florida, United States
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT05347485
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT05346835
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- Conditions
- HIV-1
- Interventions
- Drug: D/C/F/TAF FDCDrug: TAF/FTC FDCDrug: INI Based Regimen
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT04442737
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The Office of Franco Felizarta, MD, Bakersfield, California, United States
🇺🇸AIDS Health Foundation-Westside HCC, Beverly Hills, California, United States
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- Conditions
- Crohn DiseaseColitis, Ulcerative
- Interventions
- Drug: Other Biologic Therapies
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1056
- Registration Number
- NCT04372108
- Locations
- 🇺🇸
NMCP, Portsmouth, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next